---
title: "Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286958909.md"
description: "Analyst Anthony Vendetti from Maxim Group has reiterated a Buy rating on Dermata Therapeutics, maintaining a 12-month price target of $4. He cites the company's progress in launching its first skincare product, a disciplined cost structure, and sufficient liquidity into late 2026 as key factors. Despite early-stage risks, Vendetti believes the stock's valuation is attractive relative to its growth potential."
datetime: "2026-05-19T19:45:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286958909.md)
  - [en](https://longbridge.com/en/news/286958909.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286958909.md)
---

# Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Dermata Therapeutics, with a price target of $4.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Anthony Vendetti has given his Buy rating due to a combination of factors, including Dermata’s progress toward launching its first over-the-counter skincare product in the direct-to-consumer channel by mid-2026 and its disciplined cost structure, which produced lower-than-expected operating expenses and a narrower quarterly loss. He highlights that the company’s cash balance, absence of debt, and projected burn rate should provide sufficient liquidity into late 2026, supporting the execution of its commercialization plans.

Vendetti also points to the company’s Spongilla-based “Foundational” and “Clearing” treatments, ongoing proof-of-concept studies, and planned expansion into additional skin indications as drivers of long-term value. Despite acknowledging early-stage risks and applying a 25% haircut to revenue forecasts, he believes the stock’s valuation is attractive relative to its growth potential, and therefore maintains a Buy rating with an unchanged 12-month price target of $4.

### Related Stocks

- [DRMA.US](https://longbridge.com/en/quote/DRMA.US.md)
- [DRMAW.US](https://longbridge.com/en/quote/DRMAW.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results](https://longbridge.com/en/news/286141162.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)